Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single‐centre retrospective study
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18711 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, 2023. Verfasst von Alex Y Ge und 10 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Cytomegalovirus Infections. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 18 Literaturangaben. Gefördert von: University of California.
Abstract (Originalsprache)
The CD38‐targeting monoclonal antibodies (CD38 mAbs) are well‐established therapies in multiple myeloma (MM), but responses to treatment are not always deep or durable. Natural killer (NK) cells deficient in Fc epsilon receptor gamma subunits, known as g‐NK cells, are found in higher numbers among individuals exposed to cytomegalovirus (CMV) and are able to potentiate the efficacy of daratumumab in vivo. Here, we present a single‐centre, retrospective analysis of 136 patients with MM with known CMV serostatus who received a regimen containing a CD38 mAb (93.4% daratumumab and 6.6% isatuximab). CMV seropositivity was associated with an increased overall response rate to treatment regimens containing a CD38 mAb (odds ratio 2.65, 95% confidence interval [CI] 1.17–6.02). However, CMV serostatus was associated with shorter time to treatment failure in a multivariate Cox model (7.8 vs. 8.8 months in the CMV‐seropositive vs. CMV‐seronegative groups respectively, log‐rank p = 0.18, hazard ratio 1.98, 95% CI 1.25–3.12). Our data suggest that CMV seropositivity may predict better response to CD38 mAbs, although this did not correspond to longer time to treatment failure. Larger studies directly quantitating g‐NK cells are required to fully understand their effect on CD38 mAb efficacy in MM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, University of California, San Francisco, California, USA.
- Department of Epidemiology and Biostatistics, University of California, San Francisco, California, USA.
- Division of Medical Oncology, Department of Medicine, University of Washington, Seattle, Washington, USA.
- Division of Hematology and Oncology, Department of Medicine, University of California, San Francisco, California, USA.
- Department of Laboratory Medicine, University of California, San Francisco, California, USA.
- AstraZeneca, South San Francisco, California, USA.
ORCID-Profile: Alex Y Ge, Rahul Banerjee, Alfred Chung, Thomas G Martin
Förderung
- University of California
Zitieren
APA
Ge, A. Y., Huang, C. Y., Banerjee, R., Knoche, J., Chung, A., Arora, S., Martin, T. G., Wolf, J., Wong, S. W., Wiita, A. P., & Shah, N. (2023). Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single‐centre retrospective study. British Journal of Haematology. https://doi.org/10.1111/bjh.18711
Vancouver
Ge AY, Huang CY, Banerjee R, Knoche J, Chung A, Arora S, et al. Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single‐centre retrospective study. British Journal of Haematology. 2023. doi:10.1111/bjh.18711
BibTeX
@article{Ge2023,
author = {Ge, Alex Y and Huang, Chiung-Yu and Banerjee, Rahul and Knoche, Jennifer and Chung, Alfred and Arora, Shagun and Martin, Thomas G and Wolf, Jeffrey and Wong, Sandy W and Wiita, Arun P and Shah, Nina},
title = {Cytomegalovirus seropositivity is associated with improved responses to CD38 monoclonal antibody therapies in multiple myeloma: A single‐centre retrospective study},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18711}
}
EUVIMED